1. Home
  2. CTMX vs SQNS Comparison

CTMX vs SQNS Comparison

Compare CTMX & SQNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CTMX
  • SQNS
  • Stock Information
  • Founded
  • CTMX 2008
  • SQNS 2003
  • Country
  • CTMX United States
  • SQNS France
  • Employees
  • CTMX N/A
  • SQNS N/A
  • Industry
  • CTMX Biotechnology: Pharmaceutical Preparations
  • SQNS Semiconductors
  • Sector
  • CTMX Health Care
  • SQNS Technology
  • Exchange
  • CTMX Nasdaq
  • SQNS Nasdaq
  • Market Cap
  • CTMX 444.3M
  • SQNS 46.5M
  • IPO Year
  • CTMX 2015
  • SQNS 2011
  • Fundamental
  • Price
  • CTMX $2.42
  • SQNS $4.52
  • Analyst Decision
  • CTMX Strong Buy
  • SQNS Strong Buy
  • Analyst Count
  • CTMX 2
  • SQNS 1
  • Target Price
  • CTMX $5.00
  • SQNS $7.50
  • AVG Volume (30 Days)
  • CTMX 2.4M
  • SQNS 9.6M
  • Earning Date
  • CTMX 08-07-2025
  • SQNS 08-22-2025
  • Dividend Yield
  • CTMX N/A
  • SQNS N/A
  • EPS Growth
  • CTMX 128.27
  • SQNS N/A
  • EPS
  • CTMX 0.49
  • SQNS 2.16
  • Revenue
  • CTMX $147,557,000.00
  • SQNS $38,858,000.00
  • Revenue This Year
  • CTMX N/A
  • SQNS N/A
  • Revenue Next Year
  • CTMX N/A
  • SQNS $93.87
  • P/E Ratio
  • CTMX $5.36
  • SQNS $1.81
  • Revenue Growth
  • CTMX 23.81
  • SQNS 40.06
  • 52 Week Low
  • CTMX $0.40
  • SQNS $0.95
  • 52 Week High
  • CTMX $3.10
  • SQNS $5.50
  • Technical
  • Relative Strength Index (RSI)
  • CTMX 52.71
  • SQNS 87.95
  • Support Level
  • CTMX $2.33
  • SQNS $1.34
  • Resistance Level
  • CTMX $2.79
  • SQNS $2.68
  • Average True Range (ATR)
  • CTMX 0.18
  • SQNS 0.52
  • MACD
  • CTMX -0.01
  • SQNS 0.29
  • Stochastic Oscillator
  • CTMX 46.38
  • SQNS 76.77

About CTMX CytomX Therapeutics Inc.

CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.

About SQNS Sequans Communications S.A.

Sequans Communications SA is a designer, developer, and supplier of cellular semiconductor solutions for broadband Internet of Things (IoT) markets. Its offer 5G/4G chips and modules fully optimized for non-smartphone devices. The company covers applications such as smart mobility and logistics, smart utility meters, smart cities, smart industries, e-health and wellness, and smart homes to name few. The Company has one operating segment, which is the design and marketing of semiconductor components for cellular wireless systems. Its geographical segments are Taiwan, Korea, China (including Hong Kong), the Rest of Asia, the United States and the Rest of the world.

Share on Social Networks: